Read our Recent Headlines


February 16 Biotech Update

There has been some interesting news to end the week. The market seems to have recovered its footing a little and this includes the sector. There is still some work.

Dave Trading – March 2018

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

February 14 Biotech Update

It is a pretty active morning for news, so I will dive right into the events as they are pretty interesting. I am not convinced that these will be enough.

February 13 Biotech Update

The market had a nice follow through yesterday, although for some reason I do not really trust this rally (yet). It would be nice to see a couple days of.

February 12 Biotech Update

The rule of thumb is that markets never bottom on a Friday but we at least got a short term bottom as the market rallied into the close. Whether this.

February 9 Biotech Update

The broader market looks heavy and it appears that if we end the day red that the weekly losses will be accelerating. Markets do not bottom on a Friday, so.

Sarepta Official Statement Regarding The UK Study Halt

This morning, EP Vantage reported a temporary UK study halt in dosing after “one serious adverse event that could possibly be related to the investigational drug product” but the halt was for.

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!